

# Kevin Beja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11616806/publications.pdf>

Version: 2024-02-01

19  
papers

2,033  
citations

471371

17  
h-index

794469

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

3173  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	3.2	52
2	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1114-1125.	3.2	57
3	Activating <i>AKT1</i> and <i>PIK3CA</i> Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	0.9	47
4	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	26
5	Genetic and Molecular Analysis of Essential Genes in Centromeric Heterochromatin of the Left Arm of Chromosome 3 in <i>Drosophila melanogaster</i> . <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 1581-1595.	0.8	7
6	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 201-208.e1.	0.9	29
7	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	0.9	131
8	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	7.7	376
9	Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer. <i>Communications Biology</i> , 2018, 1, 122.	2.0	21
10	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. <i>Lab on A Chip</i> , 2018, 18, 1736-1749.	3.1	21
11	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	0.9	179
12	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	7.7	223
13	Genome-wide chemical mapping of O-GlcNAcylated proteins in <i>Drosophila melanogaster</i> . <i>Nature Chemical Biology</i> , 2017, 13, 161-167.	3.9	33
14	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	3.2	69
15	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
16	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
17	SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. <i>Bioinformatics</i> , 2017, 33, 26-34.	1.8	48
18	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	3.4	290

#	ARTICLE	IF	CITATIONS
19	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e233-e236.	0.9	15